Finance

Lists
Q3 2026 earnings • released • EPS miss -90.79% • Revenue beat +27.68%
See results
RNA:NASDAQ
Atrium Therapeutics Inc
$7.50
-5.78%
(-0.46) 1D
$7.50
0.00% (0.00)
After hours
Closed: Nov 12, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RNA...
Open
$7.89
High
$7.89
Low
$7.49
Mkt. cap
161.79M
Avg. vol.
249.29K
Volume
294.72K
52-wk high
$73.06
52-wk low
$7.49
EPS
-$3.86
Shares outstanding
36.14M
No. of employees
47
Open
$7.89
High
$7.89
Low
$7.49
Mkt. cap
161.79M
Avg. vol.
249.29K
Volume
294.72K
52-wk high
$73.06
52-wk low
$7.49
EPS
-$3.86
Shares outstanding
36.14M
No. of employees
47
News stories
From web sources and news partners
About Atrium Therapeutics Inc
CEO-
Employees47
Founded2025
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteatriumtherapeutics.com
Analyst ratings
Based on 4 analysts giving stock ratings to RNA in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for RNA in the last 3 months.
Highest
Current $7.50
$25.00 (+233.33%)
Average
$21.25 (+183.33%)
Lowest
$15.00 (+100.00%)
Analyst
Recommendation
Action
Price target
Projected
Date
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$20.00
+166.7%
10/28/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Initiated
$15.00
+100%
10/22/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$25.00
+233.3%
10/14/2026
Yanan Zhu
Wells Fargo
Buy
Maintained
$25.00
+233.3%
10/02/2026
David Siffringer
Cantor Fitzgerald
Buy
Initiated
$25.00
+233.3%
06/18/2026
Joseph Schwartz
Leerink Partners
Buy
Initiated
$25.00
+233.3%
05/15/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$1.20 / -$0.63
-90.79%miss
Revenue / Est. (USD)
15.32M / 12.00M
+27.68%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Jun 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
3.85M
859.00K
19.64M
3.00M
Cost of goods sold
13.29M
14.29M
16.66M
15.34M
Cost of revenue
13.29M
14.29M
16.66M
15.34M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.42M
15.67M
20.26M
10.28M
Operating expense
3.42M
15.67M
20.26M
10.28M
Total operating expenses
16.71M
29.96M
36.92M
25.62M
Operating income
-12.86M
-29.10M
-17.28M
-22.62M
Other non operating income
-15.00K
-
647.00K
328.00K
EBT including unusual items
-12.88M
-29.10M
-16.63M
-20.19M
EBT excluding unusual items
-12.88M
-29.10M
-16.63M
-20.19M
Income tax expense
-
34.00K
-
-
Effective tax rate
-
-0.12%
-
-
Other operating expenses
-
-
-
-
Net income
-12.88M
-29.14M
-16.63M
-20.19M
Net profit margin
-334.78%
-3,391.85%
-84.71%
-671.97%
Earnings per share
-
-
-
-1.18
Interest and investment income
-
-
-
2.10M
Interest expense
-
-
-
-
Net interest expenses
-
-
-
2.10M
Depreciation and amortization charges
-
-
-
-
EBITDA
-12.78M
-28.98M
-17.13M
-22.28M
Gain or loss from assets sale
-
140.00K
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps